Delayed Recovery and Increased Severity of Paclitaxel-Induced Peripheral Neuropathy in Patients With Diabetes

作者：de la Morena Barrio Pilar; Vicente Conesa Maria Angeles; Gonzalez Billalabeitia Enrique; Urrego Edgar; Garcia Garre Elisa; Garcia Martinez Elena; Zafra Poves Marta; Vicente Vicente; Ayala de la Pena Francisco

来源：Journal of the National Comprehensive Cancer Network, 2015, 13(4): 417-423.

DOI：10.6004/jnccn.2015.0057

Purpose: Although diabetes mellitus (DM) is recognized as a risk factor for chemotherapy-induced neurotoxicity, its true impact on intensity and time course of peripheral neuropathy is still unclear. The goal was to analyze the relevance of preexisting DM to weekly paclitaxelinduced peripheral neuropathy (PIPN). Methods: We performed a retrospective case-control study (1: 2) including a total of 129 patients with breast cancer (43 with DM and 86 controls) treated with single-agent weekly paclitaxel (wP). Results: Compared with controls, patients with DM treated with wP experienced PIPN more frequently (74.4% vs 58.4%; P=.016) and with higher severity (grade 2-3: 51.2% vs 27.7%; P=.014). A significant delay in PIPN resolution was observed in women with DM (P=.001) and, in a multivariate analysis, DM was the only independent predictor for delayed recovery (hazard ratio [HR], 0.16; 95% CI, 0.05-0.55; P=.003). After 2 years, 68.7% of patients with DM (vs 29.2% of women without DM) still experienced PIPN, which was functionally significant (grade 2-3) in 18.2%. Conclusions: Significantly more dose delays and reductions because of PIPN occurred in patients with DM. Preexisting DM associates with long-lasting significant PIPN in patients treated with wP. Benefits and risks of long- term significant PIPN should be carefully balanced in patients with DM before starting wP chemotherapy.

• 出版日期2015-4